PNC Financial Services Group’s Accelerate Diagnostics AXDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
– Sell
-20
Closed -$162 – 4615
2023
Q2
$162 Hold
20
– – ﹤0.01% 4674
2023
Q1
$140 Hold
20
– – ﹤0.01% 4626
2022
Q4
$141 Hold
20
– – ﹤0.01% 4670
2022
Q3
$0 Hold
20
– – ﹤0.01% 4444
2022
Q2
$0 Hold
20
– – ﹤0.01% 4480
2022
Q1
$0 Hold
20
– – ﹤0.01% 4517
2021
Q4
$1K Buy
+20
New +$1.11K ﹤0.01% 4253
2020
Q1
– Sell
-2
Closed – – 3889
2019
Q4
$0 Buy
+2
New +$330 ﹤0.01% 3980
2018
Q4
– Sell
-320
Closed -$73K – 4031
2018
Q3
$73K Hold
320
– – ﹤0.01% 2780
2018
Q2
$71K Hold
320
– – ﹤0.01% 2758
2018
Q1
$73K Hold
320
– – ﹤0.01% 2739
2017
Q4
$84K Hold
320
– – ﹤0.01% 2664
2017
Q3
$72K Hold
320
– – ﹤0.01% 2712
2017
Q2
$88K Hold
320
– – ﹤0.01% 2591
2017
Q1
$77K Hold
320
– – ﹤0.01% 2660
2016
Q4
$66K Buy
320
+250
+357% +$59.4K ﹤0.01% 2695
2016
Q3
$19K Buy
+70
New +$15.5K ﹤0.01% 3241

Other funds holding AXDX

PNC Financial Services Group's AXDX Position: Q3 2023 in Review

PNC Financial Services Group sold out of Accelerate Diagnostics (AXDX) in Q3 2023, closing a stake of 20 shares — an estimated $162 sold.

PNC Financial Services Group first reported a position in AXDX in Q3 2016 and held it in 17 quarters. The position peaked at $88K in Q2 2017. 38 funds tracked by Wall St. Rank hold AXDX as of Q3 2023.

  • PNC Financial Services Group reported no remaining Accelerate Diagnostics position as of Q3 2023 after selling out during the quarter.
  • PNC Financial Services Group sold 20 Accelerate Diagnostics shares in Q3 2023, an estimated $162.
  • PNC Financial Services Group first reported a position in Accelerate Diagnostics in Q3 2016 and held it in 17 quarters.
  • PNC Financial Services Group's Accelerate Diagnostics position peaked at $88K in Q2 2017.
  • 38 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q3 2023.

Based on PNC Financial Services Group's 13F filing for Q3 2023, filed 13 Nov 2023.